Inside Pfizer’s Drug-Pricing Deal With the Trump Administration

Pfizer's recent negotiations with the Trump administration over drug pricing have reached a critical point, showcasing the complexities of healthcare policy in the U.S. This deal highlights the ongoing discussions between pharmaceutical companies and government leaders, reflecting the broader implications for drug affordability and access for patients. As these negotiations unfold, they could set a precedent for future pricing strategies in the industry.